Data

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high risk diffuse large B-cell lymphoma and positive interim PET after 4 cycles of R-CHOP-14. (NHL21)

Health Data Australia Contributor Records
Hertzberg, Mark ; Hicks, Rodney ; Australasian Leukaemia And Lymphoma Group (ALLG) ; Australasian Leukaemia And Lymphoma Group (ALLG)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.58109/FH7F-3B31&rft.title=Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high risk diffuse large B-cell lymphoma and positive interim PET after 4 cycles of R-CHOP-14. (NHL21)&rft.identifier=http://doi.org/10.58109/FH7F-3B31&rft.publisher=Australasian Leukaemia and Lymphoma Group (ALLG)&rft.description=Dataset includes: - Full data of 149 patients with a poor prognosis of diffuse large b-cell lymphoma was analysed (151 eligible patients - 3 patients withdrawing consent) - Safety population analyzed was 151 patients (all patients that received at least 1 dose) - ECOG performance status was assessed for all 151 patients (ECOG taken pre-treatment) - Objective to demonstrated effectiveness of using PET/CT scanning to determine further treatment post 4 cycles of R-CHOP-14 treatment ○ PET/CT positive patients receiving R-ICE x 3 followed by Z-BEAM/ASCT + IF-RT ○ PET/CT negative patients recevigin R_CHOP-14 x 2 - Interim PET response of 143 patients (after 4 cycles of R-CHOP 14 - Data of Follow Up of 143 patients went for a minimum length of 0.065 months, and a maximum length of 65.22 (as months since interim PET scan)&rft.creator=Hertzberg, Mark &rft.creator=Hicks, Rodney &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.creator=Australasian Leukaemia And Lymphoma Group (ALLG) &rft.date=2023&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12609001077257&rft_subject=Predictive and prognostic markers&rft.type=dataset&rft.language=English Access the data

Full description

"Dataset includes: - Full data of 149 patients with a poor prognosis of diffuse large b-cell lymphoma was analysed (151 eligible patients - 3 patients withdrawing consent) - Safety population analyzed was 151 patients (all patients that received at least 1 dose) - ECOG performance status was assessed for all 151 patients (ECOG taken pre-treatment) - Objective to demonstrated effectiveness of using PET/CT scanning to determine further treatment post 4 cycles of R-CHOP-14 treatment ○ PET/CT positive patients receiving R-ICE x 3 followed by Z-BEAM/ASCT + IF-RT ○ PET/CT negative patients recevigin R_CHOP-14 x 2 - Interim PET response of 143 patients (after 4 cycles of R-CHOP 14 - Data of Follow Up of 143 patients went for a minimum length of 0.065 months, and a maximum length of 65.22 (as months since interim PET scan)"

Notes

HeSANDA 1.0.0

Issued: 2023

This dataset is part of a larger collection

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Australasian Leukaemia and Lymphoma Group (ALLG)

ROR : https://ror.org/05t72y326

Identifiers